DEFA14A: Masimo Nominates Christopher Chavez to Board, Extends Settlement Offer to Politan

Masimo nominates medical device veteran Christopher Chavez to its Board of Directors and extends a third settlement offer to Politan Capital Management, which was subsequently rejected.

Summary

• Masimo has nominated Christopher Chavez, a medical device executive, for election as a Class II Director at the company's 2024 Annual Meeting of Stockholders.
• This nomination follows Rolf Classon's resignation from the Board on May 10, 2024, due to health issues.
• Mr. Chavez has over 30 years of leadership experience in the medical device industry, including CEO roles at TriVascular, Inc. and Advanced Neuromodulation Systems, Inc. (ANSI).
• Masimo extended a third settlement offer to Politan Capital Management, proposing the addition of Mr. Chavez and Politan nominee William Jellison to the Board, but Politan rejected the offer.
• The company has filed a preliminary proxy statement with the SEC and intends to file and mail a definitive proxy statement to its stockholders.

Sentiment

Score: 6

Explanation: The announcement is neutral to slightly positive. The addition of an experienced director is a positive, but the ongoing disagreement with Politan introduces uncertainty.

Positives

• The addition of Christopher Chavez could bring valuable strategic, operational, and transactional expertise to the Masimo Board.
• Chavez's experience includes successfully negotiating the merger of TriVascular into Endologix, Inc. in 2016 and the sale of ANSI to St. Jude Medical in 2005 for $1.4 billion.
• Masimo's attempt to settle with Politan Capital Management demonstrates a willingness to address shareholder concerns.

Negatives

• Politan Capital Management rejected Masimo's third settlement offer, indicating continued disagreement and potential for further proxy contest.
• Rolf Classon's unexpected resignation from the Board due to health issues creates a vacancy that needs to be filled.

Risks

• Uncertainties regarding future actions that may be taken by Politan in furtherance of its nomination of director candidates for election at the 2024 Annual Meeting.
• The potential cost and management distraction attendant to Politan's nomination of director nominees at the 2024 Annual Meeting.
• Uncertainties regarding a potential separation of Masimo's Consumer Business.

Future Outlook

The company is focused on the 2024 Annual Meeting of Stockholders and potential stockholder approval of the Boards nominees. Masimo does not undertake any obligation to update, amend or clarify these statements or the Risk Factors contained in the Company's most recent reports filed with the SEC, whether as a result of new information, future events or otherwise, except as may be required under the applicable securities laws.

Management Comments

• Craig Reynolds, Masimo's Lead Independent Director, stated that Mr. Chavez would add valuable strategic, operational and transactional expertise to the Masimo Board.
• Christopher Chavez said he is excited about the prospect of joining Masimo's Board and helping the Company continue on its growth trajectory.

Industry Context

The nomination of Christopher Chavez, a seasoned medical device executive, reflects a focus on strengthening the Board with industry-specific expertise. The ongoing engagement with Politan Capital Management highlights the increasing shareholder activism in the healthcare sector.

Comparison to Industry Standards

• Masimo's board composition and engagement with activist investors are similar to trends seen in other medical device companies facing pressure to improve performance and shareholder value.
• The addition of independent directors with CEO experience is a common practice to enhance corporate governance and strategic decision-making, comparable to moves made by companies like Medtronic and Boston Scientific.

Management Changes

Stakeholder Impact

• Shareholders will have the opportunity to vote on the nominated director at the Annual Meeting.
• The outcome of the proxy contest with Politan Capital Management could impact the company's strategic direction.

Next Steps

• Masimo will file and mail a definitive proxy statement to its stockholders.
• Stockholders will vote on the election of directors at the 2024 Annual Meeting.

Key Dates

Keywords

Masimo, Board of Directors, Christopher Chavez, Politan Capital Management, Annual Meeting, Proxy Statement, Medical Device, Nomination, Settlement Offer, Corporate Governance